Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluating safety and efficacy of MMF [mycophenolate mofetil], daclizumab and corticosteroids as mainstay immunosuppression in combination with low-dose CsA [ciclosporin], Tac [tacrolimus] or Sir [sirolimus] in comparison to current standard immunosuppression (MMF, CsA and corticosteroids) in renal transplantation.

Next Previous
X
Search
Trial Profile

Evaluating safety and efficacy of MMF [mycophenolate mofetil], daclizumab and corticosteroids as mainstay immunosuppression in combination with low-dose CsA [ciclosporin], Tac [tacrolimus] or Sir [sirolimus] in comparison to current standard immunosuppression (MMF, CsA and corticosteroids) in renal transplantation.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin; Corticosteroids; Daclizumab; Immunosuppressants; Mycophenolate mofetil; Mycophenolic acid; Sirolimus; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms ELITE-SYMPHONY; SYMPHONY

    • Most Recent Events

    • 26 Jan 2010 Adverse results reported in Nephrology Dialysis Transplantation.
    • 19 May 2009 Based on the results of this study, tacrolimus has been approved for use in conjunction with mycophenolate mofetil for the prevention of kidney transplant rejection by the US FDA.
    • 27 Apr 2009 Health-related quality-of-life results published in Transplantation.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top